In anti-melanoma therapy there are three ongoing clinical trials that are recruiting patients and are using Metformin in combination with BRAF inhibitors (ClinicalTrials.gov, Identifier: NCT01638676 and NCT02143050) and also in association with Dacarbazine (ClinicalTrials.gov, Identifier: NCT02190838). The gene discussed is BRAF; the disease is melanoma.